GlassScriptPhysician profile
Katherine Totty
NPI 1164856894
$6,258.08
in general payments reported to CMS, 2019-2025
25 companies · $764 in 2025
The $764 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,175 · 2022: $1,534 · 2023: $1,183 · 2024: $1,603 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,548.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,399.38 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,107.49 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $783.40 | 2021-2025 | Farxiga, Brilinta, Andexxa |
| Merck Sharp & Dohme LLC | $738.05 | 2022-2025 | Verquvo |
| Amgen INC. | $410.62 | 2021-2025 | Repatha |
| Novo Nordisk INC | $272.13 | 2023-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $239.73 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.33 | 2021-2022 | |
| Esperion Therapeutics, INC. | $151.45 | 2021-2024 | Nexletol |
| Pfizer INC. | $137.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $115.91 | 2021-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $95.65 | 2024-2025 | Patientcare Link, Watchman Access System |
| Medtronic, INC. | $87.67 | 2022 | |
| Chiesi USA, INC. | $86.37 | 2023-2024 | Kengreal, Cleviprex |
| Abiomed | $82.13 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $69.95 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $68.98 | 2024-2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $65.53 | 2023-2024 | Evkeeza |
| Scpharmaceuticals INC. | $31.59 | 2024 | |
| Impulse Dynamics (USA) INC. | $20.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.29 | 2024 | |
| Abbott Laboratories | $19.85 | 2025 | Triclip |
| Terumo Medical Corporation | $18.17 | 2022 | |
| Inspire Medical Systems, INC. | $15.06 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Totty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.